CSL Ltd (ASX: CSL), Pro Medicus Ltd (ASX: PME), and BHP Group Ltd (ASX: BHP) shares are turning heads today.
In morning trade on Tuesday, all three of the S&P/ASX 200 Index (ASX: XJO) heavyweights are charging ahead of the 0.1% gains posted by the benchmark index.
Here's what's piquing investor interest.
Image source: Getty Images
BHP shares jump on 30% profit surge
BHP shares are leaping higher today, up 3.1% and changing hands for $64.12 apiece.
This follows the release of the ASX 200 mining giant's full-year FY 2026 results.
Among the highlights that look to have investors reaching for their buy buttons, BHP reported a 15% year-on-year increase in revenue to US$58.8 billion. And underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) of US$32.9 billion were up 27%.
The mining giant also achieved a 17% increase in its operating cash flow to US$21.8 billion.
On the bottom line, BHP shares are catching tailwinds with the miner reporting a 30% increase in underlying profit to US$13.2 billion.
On the passive income front, FY 2026 saw US$8.7 billion in dividends determined, equivalent to US$1.72 per share for a 66% payout ratio.
Pro Medicus shares leap on earnings increase
Like BHP shares, Pro Medicus shares are charging higher today following the release of the company's own FY 2026 results.
Shares in the ASX 200 health imaging company are up a whopping 10.8% at the time of writing, changing hands for $194.78
Investors are piling into Pro Medicus shares after the company reported a 22.9% year-on-year increase in revenue to $261.7 million. And underlying earnings before interest and tax (EBIT) of $196.1 million were up 24.4% from FY 2025.
This helped drive a 24.1% increase in the company's underlying net profit after tax (NPAT) to $144.7 million.
Pro Medicus also increased its cash and financial assets by 19.7% over the year to $252.3 million.
And the company's final fully-franked dividend of 37 cents per share is up 23.3% from last year's payout.
Which brings us to…
CSL shares rocket on profit outlook
Joining Pro Medicus and BHP shares in turning heads – and rocketing higher – today we find CSL.
Shares in the ASX 200 biotech giant are up an impressive 15.4% at the time of writing, trading for $155.37 each. This strong outperformance also follows on CSL's full-year earnings results.
CSL shares are shooting higher despite the company reporting a 1% year-on-year decline in revenue to US$15.8 billion. And underlying NPATA of US$3.1 billion was down 2% from FY 2025.
Still, management declared a final dividend of US$1.62 per share, in line with last year's payout.
The big uplift in CSL shares today looks to be driven by the more positive outlook for FY 2027.
"FY26 has been a year of reset. We have taken decisive action and created a clear path to return to sustainable growth," CSL interim CEO Gordon Naylor said.
Management is forecasting steady revenue in the financial year ahead, while underlying NPAT is forecast to grow by around 5%.
